Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust bolsters manufacturing leadership to expand path to commercialisation
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 1
Health & Biotech
PharmAust inks approval from Macquarie University for Open-Label MND extension study
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 3
Health & Biotech
PharmAust files groundbreaking MND/ALS clinical data with the FDA
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results
Health & Biotech
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
News
ASX February winners: The best 50 stocks as a ‘super-heroic small cap’ soars 322%
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Health & Biotech
PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy
News
Closing Bell: The ASX has come a long way and gone nowhere on Monday
News
Hot Money Monday: This is what the Father of Momentum Investing thought about ‘undervalued’ stocks
News
ASX Small Caps and IPO Weekly Wrap: The week we learned what Woolies is really worth
News
Rise and Shine: Everything you need to know before the ASX opens
News
